LINQ II Insertable Cardiac Monitor vs EchoNext
AI Verdict
Choose LINQ II Insertable Cardiac Monitor if…
Choose the Medtronic LINQ II Insertable Cardiac Monitor if you require long-term, continuous, and highly accurate heart rhythm monitoring for diagnosing infrequent or elusive arrhythmias. Its AI-powered algorithms and remote programming capabilities make it ideal for patients needing extended monitoring periods and those who benefit from remote management of their cardiac data.
View LINQ II Insertable Cardiac Monitor →Choose EchoNext if…
Choose EchoNext if you need a non-invasive, AI-powered tool to screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. It is particularly well-suited for broad access in various clinical settings, from major hospitals to community practices, to identify at-risk patients early in their care pathway.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | LINQ II Insertable Cardiac Monitor | EchoNext |
|---|---|---|
| Pricing | Enterprise | Starts at $600/month |
| Deployment | Hybrid | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
LINQ II Insertable Cardiac MonitorTool A (LINQ II) offers a hybrid deployment with both a mobile app (MyCareLink Heart) and a home communicator (MyCareLink Relay), providing flexibility for patients to transmit data. The remote programming capability also reduces the need for in-office visits, enhancing convenience for both patients and clinicians. Tool B (EchoNext) is available through the OpenEvidence platform, which is used by many clinicians, but specific details on patient-facing usability are less prominent in the provided information.
Clinical Value
EchoNextTool B (EchoNext) demonstrates superior diagnostic accuracy in detecting structural heart disease from ECGs, outperforming cardiologists even with AI assistance in studies. It has received FDA clearance for six indications, including various forms of heart failure, valve disease, and pulmonary hypertension, addressing a critical gap in early detection. While Tool A (LINQ II) offers enhanced accuracy for arrhythmia detection and false alert reduction, EchoNext's ability to identify previously undiagnosed structural heart disease from a routine, inexpensive test presents a significant clinical advancement.
Pricing & Value
EchoNextTool B (EchoNext) offers transparent tiered pricing starting at $600/month, with discounts for annual plans and add-ons for premium features. This transparency allows potential customers to understand the costs upfront. Tool A (LINQ II) uses an enterprise pricing model with no publicly disclosed details, which can make it difficult for smaller practices or those with limited budgets to assess its affordability.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness. Tool A (LINQ II) is from Medtronic, a large, established medical device company with a global presence and over a million patients worldwide using their ICMs. Tool B (EchoNext) is available through the OpenEvidence clinical decision support platform, which is used by over half a million U.S. physicians, indicating broad accessibility within healthcare systems.
Innovation
EchoNextTool B (EchoNext) represents a significant innovation by being the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a capability traditionally not possible with ECGs alone. This addresses a major unmet need in early cardiac screening. Tool A (LINQ II) offers innovative AI algorithms for enhanced accuracy and remote programming, but EchoNext's foundational shift in ECG diagnostic capabilities gives it an edge in innovation.
Support & Docs
LINQ II Insertable Cardiac MonitorTool A (LINQ II) benefits from Medtronic's extensive support infrastructure, offering patient service specialists by phone, comprehensive patient education resources, and detailed product manuals. While Tool B (EchoNext) is available through OpenEvidence, specific details regarding direct support and documentation for end-users or patients are not as explicitly outlined in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | LINQ II Insertable Cardiac Monitor | EchoNext |
|---|---|---|
| Name | LINQ II Insertable Cardiac Monitor | EchoNext |
| Company | Medtronic | Pathway Labs |
| Description | The Medtronic LINQ II is an advanced, AI-powered insertable cardiac monitor providing long-term, continuous heart rhythm monitoring with remote programming and enhanced accuracy for diagnosing arrhythmias. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AccuRhythmu2122 AI algorithms for enhanced accuracy, Remote programming capability, Up to 4.5 years of continuous monitoring, MRI compatibility (1.5 and 3.0T), MyCareLink Heartu2122 mobile app for data transmission, MyCareLink Relayu2122 home communicator option, Innovative PVC detection algorithm, Pediatric indication (ages 2+) | AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring LINQ II Insertable Cardiac Monitor and EchoNext.